MOONSTONE NUTRITION
OperatingMoonstone Nutrition Inc.
Healthcare · Pittsburgh, PA · Founded 2019
OTC remedy, designed to prevent kidney stones
Financials
FY2022–FY2025 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps markedA dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Team
14 people
Dr. Sholder received his BS at Northwestern University and his MD from the University of Illinois College of Medicine. He spent 34 years in private practice in Pittsburgh, PA, and was chief of the Division of Urology for 25 years at St. Clair Hospital in Pittsburgh. He was the Chairman of the Department of Surgery at St Clair Hospital and his special interests during his career were prostate cancer and kidney stones.
Dr. Eisner is the Co-Director of the Kidney Stone Program at MGH (Harvard Medical School). He specializes in kidney stone surgery, kidney stone prevention and related research. His clinical practice focuses on kidney stone prevention, minimally invasive and surgical treatments for kidney stones, and laparoscopic surgery. He is actively involved in research involving kidney stone prevention.
Dr. Goldfarb is the clinical chief of Nephrology at NYU, and professor of medicine at the NYU Grossman School of Medicine. He serves on the medical advisory board of the National Kidney Foundation serving Greater New York, the scientific advisory board of the Oxalosis and Hyperoxaluria Foundation, and board of directors of the International Cystinuria Foundation.
Dr. Stoller heads UCSF’s urinary stone division, which includes endourology and laparoscopy. His practice emphasizes surgical management of urinary stone disease and minimally invasive endourology. He has received the Distinction in Teaching Award from the Academic Senate at UCSF and multiple awards, including the grand prize in the annual Lapides Essay Contest in Urodynamic and Neuro-urology Research.
Marty Sholder has spent his entire corporate experience in healthcare cost containment for group health plans and workers’ compensation plans. Marty was the founder and CEO of PPO Oklahoma and WinterBrook Healthcare Management. Both companies provided cost containment strategies to insurance companies and large self-funded employers.
Noman Khan is a proven innovation, R&D and operation executive with 23 years of experience in the Food and Beverage industry. Noman has worked with and launched iconic global brands like Gatorade, Tropicana, Quaker, Ocean Spray, and Gold Peak. He also has extensive knowledge and inside experience in working with ingredients and supply chain as he led the North American Beverage R&D for Kerry foods.
Salim Rayes is an entrepreneur with 30 years’ experience across the consumer products industry. Rayes has led, scaled, and revitalized companies in the U.S. and internationally, navigating successful exits. Notable leadership positions include roles at Avalon Beverage Company (PepsiCo partner); NFPC, a $400 million UAE food & beverage company; and CRB, a $9 billion division of Giant Eagle supermarkets.
Amber Miles has 20+ years of experience in accounting and financial management, with a proven track record of delivering solutions to complex accounting and finance issues across multiple industries. Amber has led the accounting and finance departments of several Fortune 500 companies, including Rent-Way, Inc., Avery Dennison Fasson Roll Division, American Eagle Outfitters, and PNC Financial Services.
Show 5 more peopleShow fewer
Anya Sarkisov has 20+ years of experience in marketing and innovation, with a consistent track record of launching and repositioning CPG brands. She has provided integrated marketing solutions for companies such as Ford Motor Company, Miller Brewing Company, and Alpina Foods. Anya lived in Italy for 10 years where she worked for the U.S. Department of Commerce and GE Oil & Gas.
Ken Romanzi is a Board Director/Operating Partner/Strategic Advisor/CEO/President in the packaged food and beverage industry with a strong track record of delivering breakthrough results in both Fortune 500 and entrepreneurial environments including Frito-Lay (PepsiCo), Cadbury Schweppes, Nabisco (Mondelez), Ocean Spray, WhiteWave (Danone) and B&G Foods.
Mr. Abel Ang is the Group CEO of Advanced MedTech Holdings, a US$200M global player in Urology devices and services. Mr. Ang has a proven track record in the medical device sector. He has served as the Senior Advisor to the CEO of Greatbatch Inc (NYSE: ITGR), providing guidance relative to the commercialization of medical device technologies in the cardiac, neurology, vascular and orthopedic markets.
Names and titles as disclosed on StartEngine, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 2 of 2 annual reports (FY2024–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.